Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARRIER: Brolucizumab vs Aflibercept in nAMD
NCT02434328Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jul 2015
- Primary completion
- Apr 2017
- Modality
- scFv Fragments, Monoclonal Antibodies
01
Overview
A Phase 3 trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Alcon Inc.. Started Jul 2015; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02434328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02434328.